AzTrials
AzTrials

Myocardial Injury After Noncardiac Surgery (MINS)VISION-2NCT07300579

Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study 2

An observational study of Myocardial Injury After Noncardiac Surgery (MINS) and Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), run by Hamilton Health Sciences Corporation at 3 sites in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Read more about this study

Who is it for?
Ages 65 years and older
What is being tested?
Continuous vital signs measurement device
Type of treatment
Medical device
How many people
20,000 participants
Where
3 sitesCanada
Study dates
Jun 2026to Jun 2032
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Patients 65 years of age and older undergoing non-cardiac surgery with anesthesia expected to require an expected length of hospital stay of 3 or more days

Who may be able to join

  • age ≥65 years;
  • underwent non-cardiac surgery with general, neuraxial, local, or regional anesthesia; and
  • expected length of hospital stay of 3 or more days

Who cannot join

  • hearing aid(s) or cochlear implant(s) in left ear;
  • pacemaker/implantable cardioverter-defibrillator (ICD);
  • externally programmable cerebrospinal fluid shunt;
  • deep brain stimulator;
  • intolerance/allergy to adhesive;
  • history of dementia, or;
  • previous enrollment in the VISION-2 Study

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Canada3 sites
  • Hamilton General Hospital

    Hamilton, Ontario, L8L 2X2

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, L8N 4A6

  • Juravinski Hospital & Cancer Centre

    Hamilton, Ontario, L8V 1C3

Other trials in Canada

About this study

VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Following study enrollment and baseline data collection, follow up visits will occur in-hospital, at 30-days, and 1-year post-operatively.

VISION-2 has 3 primary objectives, among participants who underwent noncardiac surgery, the investigators will: 1) determine the pattern and frequency of physiological precursors (i.e., biophysical signals) to MINS, BIMS, sepsis, and infection without sepsis; 2) build prediction models from these biophysical signals and their extracted features through supervised machine learning, for the prediction and early detection of those complications; and 3) build a biobank for evaluation of novel biomarkers.

Being tested
Continuous vital signs measurement device
Medical subject headings
Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous vital signs measurement deviceDevice

    In this observational study, enrolled participants will wear the Vitaliti™ CVSM-1A device continuously before surgery, wherever and whenever possible, or as soon as possible after surgery and for up to 30-days after surgery. We will collect continuous biometric data using the Vitaliti™ CVSM-1A device. Patients, healthcare providers, data collectors, and outcome adjudicators will be blind to the Vitaliti™ data. Data from participants will be analyzed to determine the pattern and frequency of physiological precursors to outcome events. This data will be used to inform machine learning algorithms for prediction and early detection of post-surgical complications. A biobank will also be established to support exploratory proteomic and genotyping analyses to better understand biological mechanisms underlying post-operative complications.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Myocardial injury after noncardiac surgery (MINS)

    MINS not meeting 4th definition of MI is an elevated troponin measurement that occurs during the first 30 days after surgery that is judged as resulting from myocardial ischemia AND does not fulfill the MI definition. The following defines elevated troponin measurement for the diagnosis of MINS during the first 30 days after surgery: non high sensitivity Troponin T assay: ≥0.03 µg/L; high sensitivity Troponin T assay: between 20 - <65 ng/L with an absolute change ≥5 ng/L or a value ≥65 ng/L; DVIA Centaur Siemens high-sensitivity cardiac troponin I: ≥75 ng/L; ARCHITECT STAT Abbott Laboratories high-sensitivity cardiac troponin I ≥60 ng/L; other troponin assays: any measurement above the 99th percentile of the upper reference limit.

    Measured: 30 days after surgery

  2. Bleeding independently associated with mortality after noncardiac surgery (BIMS)

    A bleeding meeting any of the following 3 criteria: a) leading to a postoperative hemoglobin <70 g/L; b) requiring transfusion of one or more units of red blood cells; c) judged to be the immediate cause of death

    Measured: 30 days after surgery

  3. Sepsis

    Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria, sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: a) Glasgow Coma Scale (GCS) score of 13 or less (1 point); b) systolic blood pressure of 100 mm Hg or less (1 point); and c) respiratory rate of 22 breaths/min or more (1 point).

    Measured: 30 days after surgery

  4. Infection without sepsis

    Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.

    Measured: 30 days after surgery

Secondary outcomes (27)
  1. All-cause mortality

    Death by any cause

    Measured: 30 days after surgery

  2. Vascular mortality

    Any death with a vascular cause and includes those deaths following a myocardial infarction, cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage (i.e., hemorrhage causing cardiac tamponade, non-traumatic vascular rupture [e.g., aortic aneurism, cerebrovascular aneurism], non-stroke intracranial hemorrhage), or deaths due to an unknown cause.

    Measured: 30 days and 1 year after surgery

  3. Myocardial infarction (MI)

    The definition of myocardial infarction follows the 4th universal definition

    Measured: 30 days and 1 year after surgery

  4. Stroke

    An acute episode of neurological dysfunction consistent with an ischemic or hemorrhagic cause. For the diagnosis of stroke, the following criteria must be fulfilled: a) rapid onset of a focal/global neurologic deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphagia/aphasia, hemianopia, amaurosis, or other new neurological signs/symptoms consistent with stroke; b) the duration of a focal/global neurologic deficit is at least 24 hours, OR the neurological deficit results in death, OR there is neuroimaging evidence of a new infarct/ hemorrhage; and c) there is no other readily identifiable non-stroke cause for the clinical presentation (e.g., brain tumor, trauma, infection, hypoglycemia, peripheral lesion).

    Measured: 30 says and 1 year after surgery

  5. Proximal venous thromboembolism (VTE)

    Proximal VTE includes pulmonary embolism or proximal deep vein thrombosis.

    Measured: 30 days and 1 year after surgery

  6. Proximal deep venous thrombosis (DVT)

    The diagnosis of proximal deep venous thrombosis requires:

    Thrombosis involving the popliteal vein or more proximal veins for leg DVT or axillary or more proximal veins for arm DVTs.

    Any of the following defines evidence of vein thrombosis:

    A persistent intraluminal filling defect on contrast venography (including on computed tomography), Noncompressibility of one or more venous segments on B mode compression ultrasonography, or a clearly defined intraluminal filling defect on doppler imaging in a vein that cannot have compressibility assessed (e.g., iliac, inferior vena cava, subclavian).

    Measured: 30 days and 1 year after surgery

  7. Pulmonary embolism (PE)

    The diagnosis requires symptoms and any one of the following:

    1. a high probability ventilation/perfusion lung scan,
    2. an intraluminal filling defect of segmental or larger artery on a helical CT scan,
    3. an intraluminal filling defect on pulmonary angiography, or
    4. a positive diagnostic test for DVT (e.g., positive compression ultrasound) and one of the following:
    5. non-diagnostic (i.e., low or intermediate probability) ventilation/perfusion lung scan, or ii) non-diagnostic (i.e., subsegmental defects or technically inadequate study) helical CT scan

    Measured: 30 days and 1 year after surgery

  8. Acute kidney injury (AKI)

    Increase in serum creatinine concentration from the preoperative (pre-enrollment) concentration by either an increase of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours of surgery or an increase of 50% or greater within 7 days of surgery.

    Measured: 30 days and 1 year after surgery

  9. New acute renal failure resulting in dialysis

    New acute renal failure resulting in use of a hemodialysis machine or peritoneal dialysis apparatus

    Measured: 30 days and 1 year after surgery

  10. Acute heart failure

    Acute Heart Failure is defined as a clinical sign (i.e., at least one of the following: elevated jugular venous pressure, respiratory rales/crackles, crepitations, or presence of S3) and at least one of the following:

    1. Radiographic findings (i.e., at least one of the following: vascular redistribution, interstitial pulmonary edema, frank alveolar pulmonary edema, or multiple and diffuse bilateral B lines on ultrasonography);
    2. Elevated levels of natriuretic peptides; or
    3. Heart failure treatment implemented with diuretics with documented clinical improvement.

    Measured: 30 days and 1 year after surgery

  11. New clinically important atrial fibrillation

    The definition of clinically important atrial fibrillation requires the documentation of atrial fibrillation of any duration on an ECG or rhythm strip, which results in angina, congestive heart failure, symptomatic hypotension, or requires treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.

    Measured: 30 days and 1 year after surgery

  12. Nonfatal cardiac arrest

    Successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity requiring cardiopulmonary resuscitation, pharmacological therapy, or cardiac defibrillation.

    Measured: 30 days and 1 year after surgery

  13. Life-threatening bleeding

    Life-threatening bleeding is bleeding that is fatal or leads to: significant hypotension that requires inotrope or vasopressor therapy, or urgent (within 24 hours) surgery (other than superficial vascular repair).

    Measured: 30 days and 1 year after surgery

  14. Critical organ bleeding

    A critical organ bleeding event is bleeding that was intracranial, intraocular, intraspinal, pericardial, retroperitoneal, or intramuscular with compartment syndrome.

    Measured: 30 days and 1 year after surgery

  15. Peripheral arterial thrombosis

    The investigators will consider a peripheral arterial thrombosis to have occurred where there is clear evidence of abrupt occlusion of a peripheral artery (i.e., not a stroke, myocardial infarction, or pulmonary embolism) consistent with either an acute local thrombotic event or a peripheral arterial embolism. To fulfill this definition, the investigators require at least one of the following objective findings of peripheral arterial thrombosis:

    1. Surgical report indicating evidence of arterial thrombosis/ peripheral arterial embolism;
    2. Pathological specimen demonstrating arterial thrombosis/ peripheral arterial embolism;
    3. Imaging evidence consistent with arterial thrombosis/ peripheral arterial embolism; or
    4. Autopsy reports documenting arterial thrombosis/ peripheral arterial embolism

    Measured: 30 days and 1 year after surgery

  16. Amputation

    Any amputation procedure, or auto amputation after the initial surgery.

    Measured: 30 days and 1 year after surgery

  17. Delirium

    For the diagnosis of delirium any one of the following criteria is required:

    1. Patient meets the criteria for delirium on any in-person delirium assessment based on the Confusion Assessment Method (CAM) or any of its operationalizations (e.g., 3D-CAM, CAM-ICU); OR
    2. Positive history of delirium based on the review of hospital health records.

    Measured: 30 days and 1 year after surgery

  18. Pneumonia

    An acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.

    Measured: 30 days and 1 year after surgery

  19. Surgical site infection

    An infection that involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).

    Measured: 30 days and 1 year after surgery

  20. Urinary tract infection

    An infection that involves the urinary tract.

    Measured: 30 days and 1 year after surgery

  21. Clinically important ileus

    Physician diagnosis of functional obstruction of the gastrointestinal tract in the absence of an alternative diagnosis that leads to postoperative decreased bowel activity. The definition requires the following criteria:

    1. inability to pass flatus or stool for >24 hours; and
    2. persistence of one or more of the following signs and symptoms for >24h (abdominal distention; diffuse abdominal pain; or nausea or vomiting.

    Measured: 30 days and 1 year after surgery

  22. Falls

    Fall from standing height or walking

    Measured: 30 days and 1 year after surgery

  23. Post-discharge acute hospital care

    A composite outcome of hospital re-admission and emergency department visit, which includes urgent-care centre visit.

    Measured: 30 days after surgery

  24. Emergency department visit

    Visit to an emergency department, which includes urgent-care centre visits.

    Measured: 30 days after surgery

  25. Rehospitalization

    Admission to acute care hospital after initial discharge from hospital for index surgery.

    Measured: 30 days after surgery

  26. Sepsis

    The Third International Consensus Definitions Task Force defines sepsis as a "life-threatening organ dysfunction due to a dysregulated host response to infection." Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria, sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system:

    1. Glasgow Coma Scale (GCS) score of 13 or less (1 point),
    2. systolic blood pressure of 100 mm Hg or less (1 point), and
    3. respiratory rate of 22 breaths/min or more (1 point).

    Measured: 1 year after surgery

  27. Infection without sepsis

    Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.

    Measured: 1 year after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2025
  2. Study startJun 2026 (estimated)
  3. Primary completionJun 2031 (estimated)
  4. Study completionJun 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
20,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07300579
Sponsor's protocol ID
1.0.2026.01.13
Acronym
VISION-2
Status last verified
Apr 2026
First submitted
10 Dec 2025
Last updated
14 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Myocardial Injury After Noncardiac Surgery (MINS) and Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), run by Hamilton Health Sciences Corporation at 3 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Myocardial injury after noncardiac surgery (MINS) (time frame: 30 days after surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in